MTAP Inhibitors for Prostate and Head and Neck Cancer
Solution Overview
Problem
Current cancer treatment options for prostate and head and neck cancers are limited and often come with unfavorable side effects, such as impotence, sterility, and increased risk of tumour growth and metastasis, highlighting the need for more effective therapies.
Innovation Solution
Administration of MTAP inhibitors, specifically compounds of formula (I) or their tautomers, pharmaceutically acceptable salts, or prodrugs, which inhibit 5′-methylthioadenosine phosphorylase (MTAP), potentially combined with MTA, to selectively target and inhibit cancer cell growth while minimizing toxicity to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatment options (radical prostatectomy, radiation therapy, hormonal therapy) are used, then cancer treatment effectiveness is achieved, but severe side effects occur (impotence, sterility, bladder and rectum damage)
Solution Approach 1:
The patent changes the molecular target parameter from conventional treatment mechanisms to MTAP enzyme inhibition. By administering compounds that specifically inhibit MTAP (such as formula (I) compounds with specific nitrogen atom configurations), the treatment achieves cancer cell selectivity through biochemical parameter modification, thereby reducing physical side effects while maintaining treatment effectiveness.
2Ease of operation
If watchful waiting is used, then immediate treatment avoidance is achieved, but tumour growth and metastasis risk increases
Solution Approach 1:
The patent enables preliminary action by providing a new treatment mechanism that can be initiated before cancer becomes aggressive. The MTAP inhibitor compounds can be administered early in the disease course to prevent tumour growth and metastasis, transforming watchful waiting from passive observation to active prevention through selective enzyme inhibition.
3Productivity
If MTAP inhibitors are administered to inhibit cancer cell growth, then cancer cell proliferation is reduced, but potential toxicity to normal cells may occur
Solution Approach 1:
The patent applies local quality by creating selectivity through the specific biochemical profile of MTAP inhibitors. The compounds (such as formula (I) with specific nitrogen configurations) exhibit differential affinity for MTAP in cancer cells versus normal cells, achieving localized inhibition of cancer cell proliferation while minimizing effects on normal tissues through precise molecular targeting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MTAP inhibitors effectively inhibit cancer cell growth in vitro and in vivo, delaying tumor growth and inducing cytostasis, with minimal toxicity to normal cells, providing a promising alternative treatment for prostate and head and neck cancers.
Implementation Method 1
MTAP catalyses the reversible phosphorolysis of methylthioadenosine (MTA) to adenine and 5-methylthio-α-D-ribose-1-phosphate (MTR-1P). Inhibition of MTAP or MTAN severely limits the polyamine biosynthesis and the salvage pathway for adenine in the cells.
Data Source
AI summary
The invention relates to the treatment of cancer using an inhibitor of 5′-methylthioadenosine phosphorylase (MTAP). The invention particularly relates to the treatment of prostate cancer and head and neck cancer.